These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 15728126)

  • 21. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.
    Shi Y; Gera J; Hsu JH; Van Ness B; Lichtenstein A
    Mol Cancer Ther; 2003 Jun; 2(6):563-72. PubMed ID: 12813136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
    Caraglia M; D'Alessandro AM; Marra M; Giuberti G; Vitale G; Viscomi C; Colao A; Prete SD; Tagliaferri P; Tassone P; Budillon A; Venuta S; Abbruzzese A
    Oncogene; 2004 Sep; 23(41):6900-13. PubMed ID: 15286715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics.
    Nielsen LL; Gurnani M; Shi B; Terracina G; Johnson RC; Carroll J; Mathis JM; Hajian G
    Cancer Res; 2000 Dec; 60(24):7066-74. PubMed ID: 11156413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
    Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
    Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells.
    Frassanito MA; Cusmai A; Piccoli C; Dammacco F
    Br J Haematol; 2002 Jul; 118(1):157-65. PubMed ID: 12100143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
    O'Reilly T; McSheehy PM; Wartmann M; Lassota P; Brandt R; Lane HA
    Anticancer Drugs; 2011 Jan; 22(1):58-78. PubMed ID: 20890178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
    Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
    Shanks RH; Rizzieri DA; Flowers JL; Colvin OM; Adams DJ
    Clin Cancer Res; 2005 Jun; 11(11):4225-33. PubMed ID: 15930361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
    Cortes J; Albitar M; Thomas D; Giles F; Kurzrock R; Thibault A; Rackoff W; Koller C; O'Brien S; Garcia-Manero G; Talpaz M; Kantarjian H
    Blood; 2003 Mar; 101(5):1692-7. PubMed ID: 12411300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.
    Liesveld JL; Lancet JE; Rosell KE; Menon A; Lu C; McNair C; Abboud CN; Rosenblatt JD
    Leukemia; 2003 Sep; 17(9):1806-12. PubMed ID: 12970780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
    Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
    Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
    Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
    Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Rogers P; Boxall FE; Allott CP; Stephens TC; Kelland LR
    Eur J Cancer; 2002 Aug; 38(12):1653-60. PubMed ID: 12142057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells.
    Krzykowska-Petitjean K; Małecki J; Bentke A; Ostrowska B; Laidler P
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):537-44. PubMed ID: 22209975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
    Heinemann V
    Semin Oncol; 2002 Dec; 29(6 Suppl 20):9-16. PubMed ID: 12577228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
    Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
    Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells.
    Fotopoulou C; Baumunk D; Schmidt SC; Schumacher G
    Anticancer Res; 2010 Nov; 30(11):4619-24. PubMed ID: 21115915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.